SERPING1 and hereditary angioedema: C1-INH(SC) at the currently approved dosing significantly reduced the HAE attack rate by a median of 95% and reduced the need for rescue medication by 100% and also improved patients’ quality of life compared to placebo in the phase 3 COMPACT study [1, 5].